AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Plexus Vaccine, GSK Biologicals ink research agreement.(Brief Article)
2002 SEP 25 - (NewsRx.com & NewsRx.net) -- Plexus Vaccine, Inc., has signed a technology development agreement with GlaxoSmithKline Biologicals (GSK Bio) to explore novel approaches for structure-based rational vaccine design.
As part of the funded research collaboration, Plexus Vaccine will design chimeric miniproteins that faithfully identify and mimic the structural features of critical functional domains on target pathogenic proteins, using its proprietary structure-based vaccine design methods, and incorporating ICM molecular modeling technology from its strategic partner Molsoft, LLC.
Computational approaches include fast and accurate homology modeling, energy based loop optimization algorithms and protein surface modeling tools. Vaccine miniproteins will be designed to induce antibodies capable of highly selective binding to the target proteins, thus disrupting the pathogenic pathway. ...
- Plexus Vaccine Inc and GlaxoSmithKline Biologicals Sign Structure-Based...
- Press release article from: PR Newswire July 22, 2002 700+ words
SAN DIEGO -- Plexus Vaccine Inc announces...Biologicals (GSK Bio), Rixensart...collaboration, Plexus Vaccine will design chimeric...pathway. Plexus and GSK Bio will subsequently...product rights. "Plexus Vaccine is establishing...
- Plexus Vaccine Inc Selected to Receive Department of Defense-Funded Competitive...
- Press release article from: PR Newswire February 8, 2002 700+ words
SAN DIEGO -- Plexus Vaccine Inc, a San Diego biotechnology...amp;D funding that enables Plexus Vaccine to acquire proof of concept for...platform technology. In addition, Plexus Vaccine will receive services, including...
- Plexus Vaccine Inc Appoints Scientific Advisory Board Chaired by Roger Brent Of...
- Press release article from: PR Newswire November 1, 2001 700+ words
...DIEGO, Nov. 1 /PRNewswire/ -- Plexus Vaccine Inc, a San Diego biotechnology company...Board. Supporting Dr. Robert Deans, Plexus Vaccine's VP of Research and Development...role in helping the company employ Plexus Vaccine's Structural Pharmacogenomics technology...
- Plexus Vaccine Inc Forges Licensing Agreement With Molsoft LLC.
- Press release article from: PR Newswire September 11, 2001 700+ words
...DIEGO, Sept. 11 /PRNewswire/ -- Plexus Vaccine Inc, a San Diego biotechnology company...s molecular modeling software and Plexus Vaccine's structure-based vaccine design...Dr. Abagyan shall also join the Plexus Vaccine Board of Directors and Scientific Advisory...
- Plexus Vaccine Acquires Exclusive Position for Demographically Targeted T-cell...
- Press release article from: PR Newswire June 19, 2002 700+ words
...DIEGO and COPENHAGEN, Denmark -- Plexus Vaccine Inc, a San Diego based biotechnology...Valley centered around Copenhagen. Plexus Vaccine, formed in 2001 and based in San Diego...For additional information about Plexus Vaccine, please visit the Company's web...
- Press Release: Plexus Vaccine Inc selected to receive Department of...
- News wire article from: Chemical Business Newsbase February 8, 2002 700+ words
Plexus Vaccine Inc was chosen to receive a Department...provides R&D funding that enables Plexus Vaccine to acquire proof of concept for vaccine...platform technology. In addition, Plexus Vaccine will receive services, including...
- Press Release: Plexus Vaccine Inc and GlaxoSmithKline Biologicals sign...
- News wire article from: Asia Africa Intelligence Wire July 22, 2002 700+ words
...Business NewsBase: Press Release) Plexus Vaccine Inc has signed a technology development...the funded research collaboration, Plexus Vaccine will design chimeric miniproteins that...its strategic partner Molsoft LLC. Plexus Vaccine and GlaxoSmithKline Biologicals will...
- SIGA TECHNOLOGIES, Inc. Announces Intent to Acquire PLEXUS VACCINE Inc. to...
- Press release article from: Business Wire April 1, 2003 700+ words
...letter of intent to acquire substantially all the assets of Plexus Vaccine Inc. The acquisition would expand SIGA's capabilities...developmental timelines". Susan Burgess, President and CEO of Plexus Vaccine, is also optimistic about the competitive strength gained...
- Siga Technologies Inc announces intent to acquire Plexus Vaccine Inc to expand...
- News wire article from: Asia Africa Intelligence Wire April 1, 2003 700+ words
...letter of intent to acquire substantially all the assets of Plexus Vaccine Inc (Plexus). The acquisition would expand Siga's capabilities...delivery system for smallpox and chlamydia vaccines, while Plexus Vaccine Inc targets bacterial toxins such as those expressed by...
- SIGA Technologies, Inc. Signs Definitive Agreement to Acquire Assets of Plexus...
- Press release article from: Business Wire May 15, 2003 700+ words
...acquire substantially all of the assets of San Diego based Plexus Vaccine Inc, including the equity in Plexus's Danish subsidiary...biowarfare defense". Susan Burgess, PhD, President and CEO of Plexus Vaccine will, upon consummation of the acquisition, be named as...
Source: HighBeam Research, Plexus Vaccine, GSK Biologicals ink research agreement.(Brief Article)